Acetylsulfathiazole

When Acetylsulfathiazole Is Administered via Swine Drinking Water at High Stocking Densities

In intensive farrow-to-finish units where water medication is the primary route for group metaphylaxis, the water solubility profile of the acetylated sulfonamide directly dictates dosing precision and proportioner pump calibration. Acetylsulfathiazole dissolves as a weakly acidic species, with solubility rising from 0.48 mg/mL in pH 5.8 groundwater to 2.1 mg/mL at pH 7.8 following alkalization with trisodium phosphate or sodium carbonate buffers. Field reports from in-line Venturi medicators (Dosatron D25RE2 and G.A.S. proportional injectors) show that undissolved particulates accumulate on suction strainers when water temperature falls below 9°C, causing a deviation in actual delivered concentration of up to 18% from the set point. Compliance with the VICH GL18 (Environmental Risk Assessment) and VICH GL23 (Safety of Veterinary Drug Residues in Food) frameworks requires that the water medication system be flushed for a minimum of 120 minutes post-administration to bring organic carbon below the detection limit of 0.1 µg/L in the final rinse effluent, as per OECD 301B biodegradation testing. The standard inclusion rate for in-water delivery is 250–400 mg of acetylsulfathiazole per liter of drinking water, administered for 5 consecutive days, yielding a target daily intake of 12–20 mg/kg body weight based on a water consumption model of 0.1 L/kg BW/day for grower pigs under thermoneutral conditions.

The manufacturing process for the water-soluble powder typically begins with a wet granulation step in a high-shear mixer (Lödige FM-130 or equivalent) where acetylsulfathiazole micronized to a Dv90 ≤15 µm is blended with anhydrous lactose (spray-dried monohydrate grade) and sodium carbonate at a weight ratio of 65:30:5. The granulating fluid is a hydroalcoholic solution (isopropanol:water 80:20 v/v) added at 6–8% of the dry powder mass, precisely metered to avoid over-wetting that induces polymorphic transition of the sulfonamide from Form I to Form II, which exhibits a 22% reduction in dissolution rate as confirmed by USP Apparatus II at 50 rpm in pH 6.8 phosphate buffer. After extrusion-spheronization and fluid bed drying at an inlet temperature not exceeding 42°C (to prevent acetyl group hydrolysis, which accelerates above 48°C in the presence of alkaline carbonate), the granules are sized through a 500 µm sieve and filled into laminated foil sachets under nitrogen-flushed conditions to maintain headspace relative humidity below 15% RH. The terminal dosage form is a water-soluble granule for oral solution, typically packaged in 1 kg and 5 kg sachets for farm-scale dosing tanks, and is listed under EU Regulation 37/2010 as an allowed substance for porcine species with an MRL of 100 µg/kg in muscle tissue.

Integrated broiler operations that transition from therapeutic intervention to sub-therapeutic growth promotion or prophylactic pulse dosing through feed-grade premixes encounter a distinct set of blending and stability hurdles when acetylsulfathiazole is the selected sulfonamide. A basal diet consisting of corn-soybean meal pelleted at a conditioner temperature of 78–82°C for 45 seconds pressing time imposes thermal stress that can deacetylate 7–9% of the active ingredient to free sulfathiazole, which then participates in Maillard browning with reducing sugars to form non-bioavailable melanoidin complexes. This pathway is mitigated by applying a protective coating to the acetylsulfathiazole crystals using a fluidized-bed top-spray process with a hydrogenated palm oil melt (melting point 53–57°C) applied at 5% w/w coat mass gain, followed by immediate cooling to 22°C to seal the lipid shell. The coated active is then diluted in a stepwise geometric progression through a double-ribbon mixer (Hayes & Stolz or Forberg paddle design) to achieve a final feed concentration of 150–220 g of acetylsulfathiazole per metric ton of finished feed, equivalent to 150–220 ppm. Blend uniformity is validated according to the ISO 6497:2002 sampling protocol, requiring a coefficient of variation (CV) below 5.0% across 10 incrementally collected samples taken from the mixer discharge port at 1-minute intervals.

The carrier matrix choice exerts a dominant effect on recovery and segregation potential. Ground limestone #40 mesh with a calcium carbonate content exceeding 98% should be avoided because acetylsulfathiazole forms sparingly soluble calcium sulfathiazole chelates at the alkaline surface of the particles when moisture content rises above 2.5% w/w. In contrast, acid-washed rice hulls or vermiculite carriers pre-conditioned to a water activity (a_w) of 0.35–0.45 deliver recovery values above 94% after 6 months of warehouse storage at 40°C/75% RH accelerated conditions as per the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) GL45 bracketed stability protocol. Downstream, the premix is diluted into a complete feed in a horizontal paddle mixer with a minimum cycle time of 240 seconds to meet the homogeneity requirements of the European Feed Additives Regulation (EC) No 1831/2003 Annex II, and the final pelleted feed is analyzed by HPLC-UV at 270 nm after extraction with acidified methanol to quantify the ratio of intact acetylated form to free sulfathiazole, which must remain below 0.5% to avoid regulatory classification as a different active moiety. The terminal product is a pelleted or crumbled complete feed for broiler chickens, marketed as a medicated feed for the control of infectious coryza and fowl cholera when combined with a suitable coccidiostat.

Does the Non-Ionized Fraction Govern Absorption in Immersion Baths for Penaeid Shrimp?

Acetylsulfathiazole is applied in penaeid shrimp hatchery and early grow-out biosecurity protocols primarily as a slow-release bath treatment targeting chitinolytic Vibrio spp. proliferation on post-larval stages (PL8–PL15). The weak acid (pK_a 6.1) partitions according to the pH-partition hypothesis, and at the typical brackish water pH of 7.8–8.2 in coastal aquaculture ponds, the ionized fraction exceeds 95%, reducing transcuticular passive diffusion to less than 0.8% of the total dissolved dose. To overcome this, a pre-dissolution step in a freshwater tank is introduced: the active is solubilized in deionized water acidified with citric acid monohydrate to pH 4.8–5.2 at a concentration of 10 g/L, held for 30 minutes to allow equilibration of the neutral species, and then dosed into the larval rearing tank to achieve a final therapeutic concentration of 15–25 mg/L over a 4-hour static bath. The procedure must comply with the World Organisation for Animal Health (WOAH) Aquatic Animal Health Code Chapter 6.3 regarding responsible antimicrobial use in aquaculture, which mandates bacteriologic sampling and antibiogram confirmation prior to each treatment cycle.

The formulation is not a pre-mixed product but a point-of-use reconstitution protocol that employs a wetting agent to avoid clumping. Polysorbate 80 (Tween™ 80) is incorporated at 0.1% v/v in the acidified pre-mix, functioning as a dispersing surfactant that reduces the contact angle of the hydrophobic acetylsulfathiazole crystals below 40° as measured by sessile drop goniometry. After the immersion period, residual water is dechlorinated and passed through an activated carbon column (Norit GAC 1240, bed depth 1.2 m, empty bed contact time 25 min) before discharge, as the predicted no-effect concentration (PNEC) for freshwater invertebrates is 0.05 mg/L derived from a Daphnia magna 21-day reproduction test following OECD 211. The downstream production process is entirely implemented at the hatchery level: no finished pharmaceutical product is used, but rather a bulk technical-grade acetylsulfathiazole powder meeting the USP-NF monograph identity and assay criteria (98.0–102.0%) is weighed, dissolved, and administered via the described bath method. The terminal application is an immersion bath for shrimp larvae, registered as an extra-label use under prescribing veterinarian authority in jurisdictions following Codex Alimentarius CAC/RCP 61-2005 for fish and fishery products.

Dual-Component Injectable Suspension: Acetylsulfathiazole and Trimethoprim at 5:1 Ratio

The potentiating interaction between sulfonamides and diaminopyrimidines like trimethoprim exploits sequential blockade of folate biosynthesis, and in injectable forms, the 5:1 weight ratio of acetylsulfathiazole to trimethoprim has been adopted for treatment of bovine respiratory disease (BRD) and porcine atrophic rhinitis. Manufacturing a parenteral suspension that maintains chemical and physical stability across its shelf life requires rigorous control of particle size distribution and sterility assurance. Acetylsulfathiazole is sterilized by gamma irradiation at a minimum absorbed dose of 25 kGy (validated via EN ISO 11137-2 bioburden method, with a reference bioburden ≤100 CFU/g), while trimethoprim is milled in a jet mill under nitrogen to achieve a Dv50 ≤5 µm and then blended with the irradiated acetylsulfathiazole in a V-blender equipped with an intensifier bar rotating at 1800 rpm. The vehicle comprises propylene glycol and polyethylene glycol 400 in a 60:40 volume/volume ratio, with sodium formaldehyde sulfoxylate 0.1% w/v as an antioxidant and benzyl alcohol 1.5% v/v as a preservative. The active powders are suspended using a rotor-stator high-shear mixer (Silverson L5M-A at 8000 rpm for 12 minutes, tip speed 23 m/s) and then passed through a colloid mill with a rotor-stator gap of 0.15 mm to break any loose agglomerates before filling into multi-dose vials under Grade B ISO 14644-1 classification with a Grade A air supply.

Each milliliter of the finished sterile suspension delivers 250 mg acetylsulfathiazole and 50 mg trimethoprim, and the dosage administered is 1 mL per 15 kg body weight, translating to 16.7 mg/kg of the acetylated sulfonamide and 3.3 mg/kg of the potentiator. Syringeability through a 16G needle must be maintained after 30 days of simulated cold-chain interruption (storage cycling between 5°C and 25°C) without resuspension, a specification that demands a controlled flocculation system using oleic acid 0.05% w/w to create a loose sediment with a sedimentation volume ratio of 0.85–0.95. The drug substance is manufactured under EU GMP Part II (ICH Q7) and the finished product under Annex 1 requirements for terminally sterilized products, with the registration dossier referencing the Bioequivalence Guideline for Veterinary Medicinal Products (CVMP/VICH GL52) to support species extrapolation from the pioneer formulation. The terminal dosage form is a prolonged-action injectable suspension for intramuscular use in cattle and pigs, subject to withdrawal periods of 28 days for meat and 72 hours for milk, based on tissue residue depletion studies complying with 21 CFR Part 556 subpart B.

The deacetylation of N-acetyl sulfathiazole to generate sulfathiazole base or its water-soluble sodium salt is a critical upstream step for manufacturers who formulate oral tablets or injectable sulfathiazole sodium for fast absorption. Instead of synthesizing the heterocyclic thiazole ring from scratch, purchasing bulk acetylsulfathiazole and subsequently hydrolyzing the amide bond offers a simpler route with fewer regulated by-products, provided that the reactor engineering accounts for the acetic acid generated during hydrolysis and its potential to depress pH below the 3.5 threshold where sulfathiazole precipitates as a thick, filter-clogging polymorph. The process is conducted in a glass-lined reactor (Pfaudler or De Dietrich, 3000 L capacity) charged with acetylsulfathiazole wet cake (loss on drying 18–22% w/w), sodium hydroxide solution 30% w/w, and sufficient potable water to create a 1.2:1 molar ratio of NaOH to acetyl groups. The reaction mass is heated to 92–95°C under mild reflux for 3.5 hours, during which the liberated acetate is continuously neutralized to sodium acetate, monitored by FTIR spectroscopy for the disappearance of the carbonyl stretching band at 1680 cm⁻¹. Compliance with ICH Q11 guidelines for starting materials requires that the acetylsulfathiazole input meet an assay of ≥99.0% and total impurity content ≤0.8%, with individual unspecified impurities ≤0.10% as per the Ph. Eur. monograph for acetylated sulfonamides.

Following hydrolysis, the reaction mixture is cooled to 50°C and passed through a charcoal decolorizing filter (plate-and-frame type, precoated with diatomaceous earth, pressure differential ≤0.8 bar) to remove trace colored bodies. The filtrate is then acidified with dilute HCl (18% w/w) under high agitation to precipitate sulfathiazole free acid at pH 4.0–4.3, controlled by a process pH meter with automatic dosing logic. The slurry is centrifuged in a top-discharge basket centrifuge (Rousselet Robatel, 1200 rpm), washed with chilled acetone (2–8°C) at a wash ratio of 1.5 L/kg cake, and dried under vacuum (40–50 mbar, jacket temperature 55°C) to a moisture content below 0.5%. The overall molar yield from acetylsulfathiazole to sulfathiazole base is typically 88–92%, with the major loss attributed to mechanical entrapment in the filter cake and steam distillation of trace thiazole fragments. The terminal product is a light yellowish-white crystalline powder designated as a non-sterile active pharmaceutical ingredient, supplied in fiber drums with double polyethylene liners, and accompanied by a certificate of analysis referencing the USP 46-NF 41 monograph for sulfathiazole. It is subsequently processed into oral tablets (direct compression with croscarmellose sodium 2% w/w disintegrant) or reconstituted as the sodium salt through reaction with sodium methoxide in methanol for use in parenteral antibiotic solutions for poultry and swine.

Post-Partum Intrauterine Infusion in Dairy Cattle and pH-Buffered Gel Formulations

Metritis and retained fetal membrane sequelae in high-producing Holstein cows are managed in part by local intrauterine administration of antimicrobial suspensions, and acetylsulfathiazole has been incorporated into some geographic market formulations as a non-irritating alternative to oxytetracycline when sensitivity patterns indicate sulfonamide susceptibility. The product is manufactured as a sterile, viscous gel suspension filled into polyethylene uterine infusion syringes (capacity 60 mL) with a semi-rigid pipette tip designed to bypass the cervical canal in multiparous cows. The gel matrix is a combination of hydroxyethyl cellulose (1.8% w/w, viscosity grade 4000–6000 mPa·s in 2% solution) and xanthan gum (0.3% w/w) hydrated in water-for-injection that has been purged with nitrogen to reduce dissolved oxygen below 0.2 ppm. Acetylsulfathiazole is incorporated as a micronized powder (Dv90 ≤25 µm) at a concentration of 8.0% w/w, predispersed in a portion of the gel vehicle using a planetary mixer under vacuum (−0.85 bar) to eliminate entrapped air bubbles that would compromise syringe filling accuracy. The pH is adjusted to 5.8–6.3 with dilute sodium hydroxide, well within the physiological range of the involuting uterus, and the aqueous activity is depressed with sorbitol (15% w/w) to lower the water activity to 0.88, which inhibits the growth of Pseudomonas aeruginosa contaminants without relying solely on preservatives, as mandated by the European Pharmacopoeia 5.1.3 challenge test criteria for aqueous preparations for mucous membrane application.

Sterilization of the finished gel cannot rely on terminal autoclaving due to the heat-labile glycosidic bonds in xanthan gum; therefore, aseptic processing is followed, with the acetylsulfathiazole powder being sterilized by ethylene oxide (EtO) gas with a validated cycle (preconditioning at 50% RH, 600 mg/L EtO exposure for 6 hours at 42°C, followed by 48 hours of forced aeration at 37°C) to a sterility assurance level (SAL) of 10⁻⁶ verified by biological indicators with Bacillus atrophaeus spores as per ISO 11135:2014. The gelled vehicle components are sterilized by filtration through 0.22 µm PVDF membrane cartridges and mixed with the sterile powder in an isolator with a unidirectional airflow of 0.45 m/s. The filling operation deposits 28.0 ± 0.5 g of gel per syringe, a dose that provides 2.24 g of acetylsulfathiazole per animal. The relevant regulatory standard is the United States Code of Federal Regulations 21 CFR 530.41, which permits extralabel use of FDA-approved sulfonamide drugs in food-producing animals under the supervision of a veterinarian with an established extended withdrawal time of at least 60 days for meat and 15 days for milk, based on tissue residue depletion data generated in a GLP study. The terminal dosage form is a pre-filled intrauterine infusion syringe for dairy cattle, manufactured under an ISO 13485 quality management system with CE-marking classification as a Class IIb medical device in the EU, reflecting the dual regulatory pathway for veterinary pharmaceutical-device combinations.